Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Delivery Systems for Leishmania Vaccine Development Publisher Pubmed



Gholami E1, 2 ; Zahedifard F1 ; Rafati S1
Authors

Source: Expert Review of Vaccines Published:2016


Abstract

ABSTRACT: Leishmaniasis is a neglected disease and is endemic in tropical and sub-tropical areas worldwide. Lifelong immunity after recovery indicates that vaccination could be a promising approach to overcome the disease. Although different antigens have been successfully tested against all clinical forms, none of them have been shown to fulfill the safety and efficiency requirements for human applications. Hence, strong vehicles are needed to carry antigens of interest and potentiate its presence in the body. So far, various live or chemical carriers have been applied to reinforce the immunological effects of ideal antigens. In the current review, the recent attempts in this field have been summarized. © 2016 Informa UK Limited, trading as Taylor & Francis Group.
Related Docs
View other Related Docs
1. Development of Nano-Carriers for Leishmania Vaccine Delivery, Expert Opinion on Drug Delivery (2020)
2. The Role of Mpl and Imiquimod Adjuvants in Enhancement of Immune Response and Protection in Balb/C Mice Immunized With Soluble Leishmania Antigen (Sla) Encapsulated in Nanoliposome, Artificial Cells# Nanomedicine and Biotechnology (2018)
3. The Role of Lpd-Nanoparticles Containing Recombinant Major Surface Glycoprotein of Leishmania (Rgp63) in Protection Against Leishmaniasis in Murine Model, Immunopharmacology and Immunotoxicology (2018)
Experts (# of related papers)
View all Related Experts
Mahdi Mohebali (3)
Hossein Keshavarz Valian (2)
Other Related Docs
4. The Role of Iscomatrix Bilayer Composition to Induce a Cell Mediated Immunity and Protection Against Leishmaniasis in Balb/C Mice, Iranian Journal of Basic Medical Sciences (2016)
5. Leishmania Major P27 Gene Knockout As a Novel Live Attenuated Vaccine Candidate: Protective Immunity and Efficacy Evaluation Against Cutaneous and Visceral Leishmaniasis in Balb/C Mice, Vaccine (2019)
6. Evaluation of Immune Response Against Leishmaniasis in Balb/C Mice Immunized With Cationic Dotap/Dope/Chol Liposomes Containing Soluble Leishmania Major Antigens, Iranian Journal of Parasitology (2019)
7. Cationic Immune Stimulating Complexes Containing Soluble Leishmania Antigens: Preparation, Characterization and in Vivo Immune Response Evaluation, Iranian Journal of Immunology (2015)
8. Sphingomyelin Liposome Bearing Whole Leishmania Lysate Antigens Induce Strong Th2 Immune Response in Balb/C Mice, Iranian Journal of Basic Medical Sciences (2021)
9. Development of a New Live Attenuated Leishmania Major P27 Gene Knockout: Safety and Immunogenicity Evaluation in Balb/C Mice, Cellular Immunology (2018)
10. Immunization Against Cutaneous Leishmaniasis by Alginate Microspheres Loaded With Autoclaved Leishmania Major (Alm) and Quillaja Saponins, Iranian Journal of Pharmaceutical Research (2016)
11. Cationic Liposomes Formulated With a Novel Whole Leishmania Lysate (Wll) As a Vaccine for Leishmaniasis in Murine Model, Immunobiology (2018)
12. A Non-Pathogenic Leishmania Tarentolae Vector Based- Hcv Polytope Dna Vaccine Elicits Potent and Long Lasting Th1 and Ctl Responses in Balb/C Mice Model, Molecular Immunology (2019)
13. Coadminstration of L. Major Amastigote Class I Nuclease (Rlmacin) With Lpd Nanoparticles Delays the Progression of Skin Lesion and the L. Major Dissemination to the Spleen in Balb/C Mice-Based Experimental Setting, Acta Tropica (2016)
14. Leishmania Tarentolae Secreting the Sand Fly Salivary Antigen Ppsp15 Confers Protection Against Leishmania Major Infection in a Susceptible Balb/C Mice Model, Molecular Immunology (2015)
15. Pegylation of Cationic Liposomes Encapsulating Soluble Leishmania Antigens Reduces the Adjuvant Efficacy of Liposomes in Murine Model, Parasite Immunology (2017)
16. Combinatorial Delivery of Antigen and Tlr Agonists Via Plga Nanoparticles Modulates Leishmania Major-Infected-Macrophages Activation, Biomedicine and Pharmacotherapy (2021)
17. Multi-Antigen Vaccination With Lpd Nanoparticles Containing Rgp63 and Rlmac1n Proteins Induced Effective Immune Response Against Leishmaniasis in Animal Model, Journal of Drug Delivery Science and Technology (2021)
18. A Phospholipase-A Activity in Soluble Leishmania Antigens Causes Instability of Liposomes, Current Drug Delivery (2020)
19. Dna Plasmid Coding for Phlebotomus Sergenti Salivary Protein Pssp9, a Member of the Sp15 Family of Proteins, Protects Against Leishmania Tropica, PLoS Neglected Tropical Diseases (2019)
20. Live Attenuated Leishmania Infantum Centrin Deleted Mutant (Licen-/-) As a Novel Vaccine Candidate: A Field Study on Safety, Immunogenicity, and Efficacy Against Canine Leishmaniasis, Comparative Immunology# Microbiology and Infectious Diseases (2023)